首页 > 市场调查报告书 > 医疗设备

药物递输设备 DDS

市场调查报告书

商品编码

1795652

药物输送的全球市场:药物用量，药价，销售额，临床试验趋势(2030年)

Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales & Clinical Trials Insight 2030

出版日期: 2025年08月01日 | 出版商:

KuicK Research | 英文 900 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

药物输送的全球市场:药物用量，药价，销售额，临床试验趋势(2030年)报告观察和亮点:

研究方法
全球及区域市场概览
全球市场规模（十亿美元）：2022-2030 年
全球市场机会：超过 900 亿美元
临床试验中控释药物的洞见：超过 190 种产品
按公司、适应症和阶段划分的全球控释药物临床管线
已获批准和上市的控释药物的洞察：超过 180 种产品
控释药物的剂量、定价与销售洞察
竞争激烈前景

控释系统需求及本报告意义

随着医护人员和病患寻求更优质、更便捷、更安全的治疗方案，对控释系统的需求日益增长。糖尿病、心血管疾病和神经系统疾病等慢性疾病需要长期治疗，而传统给药方式的限制（例如重复给药和药物吸收不稳定）往往会降低疗效。控释系统透过长时间维持稳定的药物浓度、最大限度地减少给药频率和提高疗效来解决这些问题。控释系统还有助于减少副作用、提高患者依从性并优化药物药物动力学。

本报告深入探讨了控释给药技术不断发展的前景，重点介绍了创新技术、临床趋势和关键市场参与者。随着对改进药物输送的需求不断增长，本分析将为这个不断增长的市场提供未来成长和机会的洞察。除了最新的技术发展和新兴趋势外，该报告还包含 60 多种药物的详细定价数据以及特定产品的销售业绩数据。这些策略建议和市场数据的结合，有助于市场参与者在药物开发、交付和商业化方面做出明智的决策。

报告中包含的临床试验洞察

临床试验对于验证控释药物传递系统的有效性和安全性至关重要。本报告对几项关键临床试验进行了深入分析，并展望了该领域的发展。本部分提供的资讯包括试验阶段、申办者、地理分布、技术提供者、合作者和许可证持有者。试验涵盖了从疼痛管理和肿瘤学到神经系统和代谢疾病等各种治疗类别。

活跃于控释药物输送系统研发的主要公司

目前，许多大型製药和生技公司都在致力于控释药物输送系统的开发。这些公司是研发领域的领导者，采用先进技术开发更有效率、更方便患者的药物。本报告列举了艾伯维、阿斯特捷利康和默克等知名公司，它们正在探索新的药物传递平台，以增强慢性病、癌症、神经系统疾病和代谢性疾病的治疗效果。

除了大型製药公司外，一些规模较小的新创公司也在开发新型控释系统方面处于领先地位。 SpyGlass Pharma 和 Glaukos Corporation 等公司正在课题眼科领域控释平台的局限性，而勃林格殷格翰和 Re-Vana Therapeutics 等合作伙伴正在开发用于治疗视网膜疾病的可生物降解植入物。我们也讨论了这些合作如何推动新一代药物递送系统的商业化。

报告展示了控释药物递送系统领域的未来发展方向

预期控释药物递送系统未来将迎来显着的成长和发展。报告指出，生物技术和数位医疗的进步将推动更个人化、更有针对性的药物传递机制的应用。精准医疗的兴起将推动客製化药物输送系统的研发，以满足每位患者的需求，从而进一步提高治疗效果和患者依从性。

此外，我们的研究预测，包括植入式系统和透皮贴片在内的非侵入性药物传递技术因其便利性和患者不适感最小而将得到更广泛的应用。神经退化性疾病、个人化肿瘤治疗和罕见疾病领域应用的不断扩展也有望推动市场向前发展。

持续的研发投入和对创新药物输送技术的监管支持力度的加大，将维持受控药物输送系统市场的成长，为开发这些先进疗法的公司提供重大机会。

AbbVie
Antlia Bioscience
Arbor Pharmaceuticals (Azurity Pharmaceuticals)
AstraZeneca
Bausch Health Companies
Biodexa Pharmaceuticals
Boehringer Ingelheim
Camurus
DURECT Corporation
Emplicure
HLK Pharmacin
Jemincare
Johnson & Johnson
Luye Pharma Group
Lyndra
Mallinckrodt plc
MedinCell S.A.
Merck
Otsuka Pharmaceutical
Pacira BioSciences
Pfizer
Purdue Pharma
Roche
Sanofi
Serina Therapeutics
Sun Pharmaceutical Industries
Supernus Pharmaceuticals
Takeda
Tris Pharma
ViiV Healthcare

简介目录图表

Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales & Clinical Trials Insight 2030 Report Finding & Highlights:

Research Methodology
Global & Regional Market Overview
Global Market Size Insight In US$ Billion: 2022 - 2030
Global Market Opportunity: > US$ 90 Billion
Insight On Controlled Release Drugs In Clinical Trials: > 190 Drugs
Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase
Insight On Approved & Marketed Controlled Release Drugs: > 180 Drugs
Controlled Release Drugs Dosage, Pricing & Sales Insight
Competitive Landscape

Need for Controlled Drug Release Systems & Why This Report?

The demand for controlled drug release systems has increased as both healthcare practitioners and patients seek improved, more convenient, and safer therapeutic regimens. Chronic diseases like diabetes, cardiovascular diseases, and neurological disorders call for long-term therapy, and the limitations associated with conventional dosing, such as repeated administration and variable drug absorption, frequently undermine treatment efficacy. Controlled drug release systems resolve these issues by maintaining uniform levels of drugs for a prolonged duration, minimizing the frequency of dosing, and improving the therapeutic efficacy. Controlled drug release systems also assist in the reduction of side effects, patient compliance, and the optimization of the pharmacokinetics of drugs.

This report gives an in-depth look at the changing landscape of drug controlled release technologies, underlining the innovations, clinical trends, and key market players. With the demand for improved drug delivery increasing, this analysis is an eye opener to future growth and opportunities in this growing market. Apart from the latest technological developments and emerging trends, it also contains in-depth pricing data for more than 60 medicines, as well as sales performance data for specific products. This blend of strategic recommendations and market data is meant to guide industry participants, enabling them to make informed decisions in drug development, delivery, and commercialization.

Clinical Trials Insight Included In Report

Clinical trials are crucial in validating the efficacy and safety of drug delivery systems with controlled release. There are detailed insights into several key clinical trials in this report, and giving a preview of the development in the area. The information provided in this section specifically comprises stages of trials, sponsors, geographical distribution, technology providers, collaborators and license holders. The trials cover a variety of therapeutic categories, including pain management and oncology to neurological diseases and metabolic disorders.

Major Companies Active In R&D of Controlled Drug Release Systems

A number of major pharmaceutical and biotech firms are currently engaged in the development of controlled drug release systems. These firms are leaders in R&D activities, employing advanced technologies to develop more efficient and patient-friendly medicines. The report identifies prominent players like AbbVie, AstraZeneca, and Merck, which are looking for novel drug delivery platforms to enhance the treatment of chronic diseases as well as conditions like cancer, neurological disorders, and metabolic disorders.

Along with major pharmaceutical firms, smaller startups are also taking lead in creating new controlled release systems. Firms such as SpyGlass Pharma and Glaukos Corporation are pushing the boundaries of controlled-release platforms in ophthalmology, whereas partnerships like that of Boehringer Ingelheim with Re-Vana Therapeutics are developing biodegradable implants for retinal illnesses. The report also explains how these collaborations are spurring the commercialization of new-generation drug delivery systems.

Report Indicating Future Direction Of Controlled Drug Release Systems Segment

The future for controlled drug release systems promises significant growth and development. According to the report, the emphasis will be placed on the use of more personalized and targeted drug delivery mechanisms, sparked by developments in biotechnology and digital health technologies. The advent of precision medicine will propel the creation of customized drug release systems that respond to each patient's requirements, even further enhancing the effectiveness of treatment and patients' compliance.

Moreover, our research anticipates a wider use of non-invasive drug delivery techniques, including implantable systems and transdermal patches, as they are convenient and cause less discomfort to patients. Increasing applications in neurodegenerative disorders, personalized oncology, and rare diseases will also propel the market forward.

As investment in R&D continues and regulatory backing for innovative drug delivery technologies is further enhanced, controlled drug release system market growth will persist, presenting substantial opportunities for firms developing such sophisticated therapies.

1. Introduction To Controlled Drug Delivery

1.1 Fundamentals & Technology
1.2 Classification By System, Route & Technology
1.3 Mechanisms Of Action

2. Material Based Approaches For Controlled Drug Delivery

2.1 Polymers
2.2 Chronopharmaceutics
2.3 Nanoparticulate Delivery System

3. Global Controlled Release Drug Delivery Market Trends

3.1 Current Market Scenario
3.2 Future Market Outlook

4. Controlled Drug Delivery Research & Clinical Trends By Indication

4.1 Neurological Disorders
4.2 Cardiovascular Diseases
4.3 Diabetes
4.4 Cancer
4.5 Microbial Infections

5. Global Controlled Release Drug Market Trends By Region

5.1 US
5.2 Europe
5.3 Japan
5.4 China
5.5 Canada
5.6 South Korea

6. Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-II/III
6.7 Phase-III
6.8 Preregistration
6.9 Registered

7. Marketed Controlled Release Drugs Clinical Insight By Company, Country & Indication

8. Controlled Release Drugs for Alzheimer's Disease - Pricing & Dosage Insight

8.1 Namzaric (Extended-Release)
8.2 Namenda XR (Extended-Release)
8.3 Razadyne ER (Extended Release)

9. Controlled Release Drugs for Parkinson's Disease - Pricing & Dosage Insight

9.1 Gocovri (Extended-Release)
9.2 Osmolex ER (Extended-Release)
9.3 Mirapex ER (Extended-Release)

10. Controlled Release Drugs for Schizophrenia - Pricing & Dosage Insight

10.1 Invega (Extended-Release)
10.2 Invega Franchise/Invega Hafyera (Extended-Release)
10.3 Seroquel XR (Extended-Release)
10.4 Abilify Franchise (Extended-Release)
10.5 Aristada/Aristada Initio (Extended-Release)
10.6 Rykindo (Extended-Release)
10.7 Risperdal Consta (Extended-Release)
10.8 Uzedy (Extended-Release)

11. Controlled Release Drugs for Chronic & Post-Operative Pain - Pricing & Dosage Insight

11.1 Hysingla ER (Extended-Release)
11.2 Nucynta ER (Extended-Release)
11.3 Kadian (Extended-Release)
11.4 Xtampza ER (Extended-Release)
11.5 MS Contin (Extended-Release)
11.6 Embeda (Extended-Release)
11.7 Posimir (Sustained-Release)
11.8 Zynrelef (Extended-Release)
11.9 ConZip (Extended-Release)
11.10 Generic Hydromorphone (Extended-Release)

12. Controlled Release Drugs for Multiple Sclerosis - Pricing & Dosage Insight

12.1 Ampyra / Fampyra (Extended-Release)
12.2 Tecfidera (Delayed-Release)
12.3 Vumerity (Delayed-Release)
12.4 Rayos (Delayed-Release)
12.5 Bafiertam (Delayed-Release)

13. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing & Dosage Insight

13.1 Glumetza (Extended-Release)
13.2 Glucotrol XL (Extended-Release)
13.3 Glucophage XR (Extended-Release)
13.4 Trijardy XR (Extended-Release)
13.5 Synjardy XR (Extended-Release)

14. Controlled Release Drugs for Cardiovascular Diseases - Pricing & Dosage Insight

14.1 Procardia XL (Extended-Release)
14.2 Toprol XL (Extended-Release)
14.3 Verelan PM (Extended-Release)
14.4 Cardizem LA (Extended-Release)
14.5 Calan SR (Sustained-Release)
14.6 Altoprev (Extended-Release)
14.7 Cardura XL (Extended-Release)

15. Controlled Release Drugs for HIV - Pricing & Dosage Insight

15.1 Apretude (Extended-Release)
15.2 Cabenuva (Extended-Release)
15.3 Rukobia (Extended-Release)

16. Controlled Release Drugs for Attention Deficit Hyperactivity Disorder - Pricing & Dosage Insight

16.1 Qelbree (extended-release)
16.2 Jornay PM (Extended-Release)
16.3 Cotempla XR-ODT (Extended-Release)
16.4 Adzenys XR-ODT (Extended-Release)
16.5 Intuniv (Extended-Release)
16.6 Focalin XR (Extended-Release)

17. Controlled Release Drugs for Inflammatory & Autoimmune Diseases - Pricing & Dosage Insight

17.1 Rinvoq (Extended-Release)
17.2 Ortikos (Extended-Release)
17.3 Xeljanz XR (Extended-Release)
17.4 Mestinon Timespan (Extended-Release)
17.5 Symax Duotab (Extended-Release)

18. Controlled Release Drugs for Bacterial Infections - Pricing & Dosage Insight

18.1 Aemcolo (Delayed-Release)
18.2 Talicia (Delayed-Release)

19. Controlled Release Drugs for Opioid Use Disorder - Pricing & Dosage Insight

19.1 Sublocade (Sustained-Release)
19.2 Brixadi (Extended-Release)

20. Controlled Release Drugs for Preventing Organ Transplant Rejection - Pricing & Dosage Insight

20.1 Astagraf XL (Extended-Release)
20.2 Envarsus XR (Extended-Release)

21. Controlled Release Drugs for Migraine & Seizure - Pricing & Dosage Insight

21.1 Trokendi XR (Extended-Release)
21.2 Oxtellar XR (Extended-Release)
21.3 Keppra XR (Extended-Release)
21.4 Roweepra XR (Extended-Release)
21.5 Depakote, Depakote ER, & Depakote Sprinkles

22. Controlled Release Drugs for Mental Health and Sleep Disorders - Pricing & Dosage Insight

22.1 Effexor XR (Extended-Release)
22.2 Xanax XR (Extended-Release)
22.3 Ambien CR (Extended-Release)

23. Controlled Release Drugs for Metabolic and Electrolyte Disorders - Pricing & Dosage Insight

23.1 Klor-Con 8, Klor-Con 10, Klor-Con M10, Klor-Con M15, Klor-Con M20

24. Global Controlled Drug Delivery System Market Dynamics

24.1 Market Drivers & Opportunities
24.2 Market Challenges & Restraints

25. Competitive Landscape

25.1 AbbVie
25.2 Antlia Bioscience
25.3 Arbor Pharmaceuticals (Azurity Pharmaceuticals)
25.4 AstraZeneca
25.5 Bausch Health Companies
25.6 Biodexa Pharmaceuticals
25.7 Boehringer Ingelheim
25.8 Camurus
25.9 DURECT Corporation
25.10 Emplicure
25.11 HLK Pharmacin
25.12 Jemincare
25.13 Johnson & Johnson
25.14 Luye Pharma Group
25.15 Lyndra
25.16 Mallinckrodt plc
25.17 MedinCell S.A.
25.18 Merck
25.19 Otsuka Pharmaceutical
25.20 Pacira BioSciences
25.21 Pfizer
25.22 Purdue Pharma
25.23 Roche
25.24 Sanofi
25.25 Serina Therapeutics
25.26 Sun Pharmaceutical Industries
25.27 Supernus Pharmaceuticals
25.28 Takeda
25.29 Tris Pharma
25.30 ViiV Healthcare

简介目录图表

List of Figures

Figure 1-1: Conventional Drug Delivery Systems - Limitations
Figure 1-2: Novel Drug Delivery Platform Diversification
Figure 1-3: Evolution Of Drug Delivery Technology: 1st to 3rd Generation
Figure 1-4: Challenges Addressed By Third Generation Drug Delivery
Figure 1-5: Targeted vs. Non-Targeted Drug Delivery
Figure 1-6: Zero-Order Controlled Drug Release
Figure 1-7: Plasma Concentration-Time Profile: Conventional vs. Controlled Release
Figure 1-8: Comparison Of Modified Drug Release Systems
Figure 1-9: Pulsatile Drug Release Mechanism In Pulsincap
Figure 1-10: Classification By Technical Complexity
Figure 1-11: Structural Differences Among Drug Delivery Systems
Figure 1-12: Classification By Route of Administration
Figure 1-13: Types Of Diffusion-Controlled Mechanisms
Figure 1-14: Encapsulation Dissolution-Controlled Mechanism
Figure 1-15: Osmotic Controlled Drug Release
Figure 1-16: Erosion Mechanisms In Matrix Systems
Figure 2-1: Polymeric Controlled Drug Delivery Devices - Categories
Figure 2-2: Nanostructures For Nanoparticulate Delivery Systems
Figure 3-1: Global - Controlled Release Drug Delivery Market Size (US$ Billion), 2022 - 2025
Figure 3-2: Global - Controlled Release Drug Delivery Market Forecast (US$ Billion), 2026 - 2030
Figure 4-1: Major Non-Invasive Routes For Insulin Delivery
Figure 4-2: Controlled Drug Delivery Strategies In Cancer Therapy
Figure 6-1: Global - Controlled Release Drug Clinical Pipeline By Phase (Number), 2025 Till 2030
Figure 8-1: Namzaric - Price Per Unit & Supply (US$), August'2025
Figure 8-2: Generic Donepezil/Memantine - Price Per Unit & Supply (US$), August'2025
Figure 8-3: Namenda XR - Price Per Unit & Supply Of 7mg & 21mg Extended Release Capsules (US$), August'2025
Figure 8-4: Namenda XR - Price Per Unit & Supply Of 14mg & 28mg Extended Release Capsules (US$), August'2025
Figure 8-5: Namenda XR - Price Per Unit & Supply Of Extended Release Oral Kit (US$), August'2025
Figure 8-6: Generic Memantine - Price Per Unit & Supply Of 7mg & 21mg Extended Release Capsules (US$), August'2025
Figure 8-7: Generic Memantine - Price Per Unit & Supply Of 14mg Extended Release Capsules (US$), August'2025
Figure 8-8: Generic Memantine - Price Per Unit & Supply Of 28mg Extended Release Capsules (US$), August'2025
Figure 8-9: Razadyne ER - Price Per Unit & Supply (US$), August'2025
Figure 8-10: Generic Galantamine - Price Per Unit & Supply (US$), August'2025
Figure 9-1: Gocovri - Price Per Unit & Supply (US$), August'2025
Figure 9-2: Global - Gocovri Annual Sales (US$ Million), 2021-2025
Figure 9-3: Global - Gocovri Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 9-4: Global - Gocovri Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 9-5: Osmolex ER - Price Per Unit & Supply Of 322 mg Extended Release Tablet (US$), August'2025
Figure 9-6: Osmolex ER - Price Per Unit & Supply Of 129 mg Extended Release Tablet (US$), August'2025
Figure 9-7: Osmolex ER - Price Per Unit & Supply Of 193 mg Extended Release Tablet (US$), August'2025
Figure 9-8: Osmolex ER - Price Per Unit & Supply Of 258 mg Extended Release Tablet (US$), August'2025
Figure 9-9: Mirapex ER - Available Dosage Strengths (mg)
Figure 9-10: Mirapex ER - Price Per Unit & Supply Of 0.375 mg & 0.75 mg Extended Release Tablets (US$), August'2025
Figure 9-11: Mirapex ER - Price Per Unit & Supply Of 1.5 mg Extended Release Tablet (US$), August'2025
Figure 9-12: Mirapex ER - Price Per Unit & Supply Of 2.25 mg, 3 mg, 3.75 mg & 4.5 mg Extended Release Tablets (US$), August'2025
Figure 9-13: Generic Pramipexole - Price Per Unit & Supply Of 0.375 mg & 0.75 mg (US$), August'2025
Figure 9-14: Generic Pramipexole - Price Per Unit & Supply Of 1.5 mg, 2.25 mg, 3 mg, & 4.5 mg (US$), August'2025
Figure 9-15: Generic Pramipexole - Price Per Unit & Supply Of 3.75 mg (US$), August'2025
Figure 10-1: Invega - Available Dosage Strengths (mg)
Figure 10-2: Invega - Price Per Unit & Supply (US$), August'2025
Figure 10-3: Invega Sustenna - Price Per Unit & Supply (US$), August'2025
Figure 10-4: Invega Trinza - Price Per Unit & Supply (US$), August'2025
Figure 10-5: Invega Hafyera - Price Per Unit & Supply (US$), August'2025
Figure 10-6: Global - Invega Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-7: Global - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 10-8: Global - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 10-9: US - Invega Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-10: US - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 10-11: US - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 10-12: ROW - Invega Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-13: ROW - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 10-14: ROW - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 10-15: Seroquel XR - Available Dosage Strengths (mg)
Figure 10-16: Seroquel XR - Price Per Unit & Supply (US$), August'2025
Figure 10-17: Generic Quetiapine - Price Per Unit & Supply Of 60 Tablets (US$), August'2025
Figure 10-18: Generic Quetiapine - Price Per Unit & Supply Of 100 Tablets (US$), August'2025
Figure 10-19: Global - Seroquel XR Total Annual Sales (US$ Million), 2020-2021
Figure 10-20: Abilify Maintena - Available Dosage Strengths (mg)
Figure 10-21: Abilify Maintena - Price Per Supply of Vial & Prefilled Syringe (US$), August'2025
Figure 10-22: Abilify Asimtufii - Price Per Unit & Supply (US$), August'2025
Figure 10-23: Global - Abilify Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-24: Global - Abilify Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 10-25: Global - Abilify Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 10-26: Aristada - Available Dosage Strengths (mg)
Figure 10-27: Aristada - Price Per Unit & Supply (US$), August'2025
Figure 10-28: Aristada Initio - Price Per Unit & Supply (US$), August'2025
Figure 10-29: Global - Aristada Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-30: Global - Aristada Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 10-31: Global - Aristada Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 10-32: Rykindo - Available Dosage Strengths (mg)
Figure 10-33: Rykindo - Price Per Supply (US$), August'2025
Figure 10-34: Generic Risperidone - Price Per Supply (US$), August'2025
Figure 10-35: Risperdal Consta - Price Per Supply (US$), August'2025
Figure 10-36: Global - Risperdal Consta Annual Sales (US$ Million), 2020-2021
Figure 10-37: Uzedy - Price Per Unit & Supply (US$), August'2025
Figure 11-1: Hysingla ER - Available Dosage Strengths (mg)
Figure 11-2: Hysingla ER - Price Per Unit & Supply (US$), August'2025
Figure 11-3: Generic Hydrocodone - Price Per Unit & Supply (US$), August'2025
Figure 11-4: Nucynta ER - Available Dosage Strengths (mg)
Figure 11-5: Nucynta ER - Price Per Unit & Supply (US$), August'2025
Figure 11-6: Global - Nucynta ER Annual Sales (US$ Million), 2020-2025
Figure 11-7: Global - Nucynta ER Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-8: Global - Nucynta ER Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-9: Kadian - Available Dosage Strengths (mg)
Figure 11-10: Kadian - Price Per Unit & Supply Of Strength 10 mg/12 hr (US$), August'2025
Figure 11-11: Kadian - Price Per Unit & Supply Of Strength 10 mg/12 to 24 hr & 10 mg/24 hr (US$), August'2025
Figure 11-12: Kadian - Price Per Unit & Supply Of Strength 20 mg/12 hr (US$), August'2025
Figure 11-13: Kadian - Price Per Unit & Supply Of Strength 20 mg/12 to 24 hr & 20 mg/24 hr (US$), August'2025
Figure 11-14: Kadian - Price Per Unit & Supply Of Strength 30 mg/12 hr (US$), August'2025
Figure 11-15: Kadian - Price Per Unit & Supply Of Strength 30 mg/12 to 24 hr & 30 mg/24 hr (US$), August'2025
Figure 11-16: Kadian - Price Per Unit & Supply Of Strength 40 mg/12 to 24 hr & 40 mg/24 hr (US$), August'2025
Figure 11-17: Kadian - Price Per Unit & Supply Of Strength 50 mg/12 hr (US$), August'2025
Figure 11-18: Kadian - Price Per Unit & Supply Of Strength 50 mg/12 to 24 hr & 50 mg/24 hr (US$), August'2025
Figure 11-19: Kadian - Price Per Unit & Supply Of Strength 60 mg/12 hr (US$), August'2025
Figure 11-20: Kadian - Price Per Unit & Supply Of Strength 60 mg/12 to 24 hr (US$), August'2025
Figure 11-21: Kadian - Price Per Unit & Supply Of Strength 60 mg/24 hr (US$), August'2025
Figure 11-22: Kadian - Price Per Unit & Supply Of Strength 70 mg/12 to 24 hr (US$), August'2025
Figure 11-23: Kadian - Price Per Unit & Supply Of Strength 80 mg/12 hr, 80 mg/12 to 24 hr & 80 mg/24 hr (US$), August'2025
Figure 11-24: Kadian - Price Per Unit & Supply Of Strength 100 mg/12 hr, 100 mg/12 to 24 hr & 100 mg/24 hr (US$), August'2025
Figure 11-25: Kadian - Price Per Unit & Supply Of Strength 130 mg/12 to 24 hr & 150 mg/12 to 24 hr (US$), August'2025
Figure 11-26: Kadian - Price Per Unit & Supply Of Strength 200 mg/12 to 24 hr & 200 mg/24 hr (US$), August'2025
Figure 11-27: Xtampza ER - Available Dosage Strengths (mg)
Figure 11-28: Xtampza ER - Price Per Unit & Supply (US$), August'2025
Figure 11-29: Global - Xtampza ER Annual Sales (US$ Million), 2020-2025
Figure 11-30: Global - Xtampza ER Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-31: Global - Xtampza ER Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-32: MS Contin - Available Dosage Strengths (mg)
Figure 11-33: MS Contin - Price Per Unit & Supply (US$), August'2025
Figure 11-34: Embeda - Price Per Unit & Supply (US$), August'2025
Figure 11-35: Zynrelef - Price Per Unit & Supply (US$), August'2025
Figure 11-36: Global - Zynrelef Annual Sales (US$ Million), 2021-2025
Figure 11-37: Global - Zynrelef Quarterly Sales (US$ Million), H1'2025
Figure 11-38: Global - Zynrelef Quarterly Sales (US$ Million), 2024
Figure 11-39: ConZip - Available Dosage Strengths (mg)
Figure 11-40: ConZip - Price Per Unit & Supply (US$), August'2025
Figure 11-41: Generic Hydromorphone - Available Dosage Strengths (mg)
Figure 11-42: Generic Hydromorphone - Price Per Unit & Supply (US$), August'2025
Figure 12-1: Ampyra - Price Per Unit & Supply (US$), August'2025
Figure 12-2: Generic Dalfampridine - Price Per Unit & Supply (US$), August'2025
Figure 12-3: ROW - Fampyra Annual Sales (US$ Million), 2020-2025
Figure 12-4: ROW - Fampyra Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-5: Tecfidera - Available Dosage Strengths (mg)
Figure 12-6: Tecfidera - Price Per Unit & Supply (US$), August'2025
Figure 12-7: Generic Dimethyl Fumarate - Price Per Unit & Supply (US$), August'2025
Figure 12-8: Global - Tecdifera Annual Sales (US$ Million), 2020-2025
Figure 12-9: Global - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-10: Global - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-11: US - Tecdifera Annual Sales (US$ Million), 2020-2025
Figure 12-12: US - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-13: US - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-14: ROW - Tecdifera Annual Sales (US$ Million), 2020-2025
Figure 12-15: ROW - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-16: ROW - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-17: Vumerity - Price Per Unit & Supply (US$), August'2025
Figure 12-18: Global - Vumerity Annual Sales (US$ Million), 2020-2025
Figure 12-19: Global - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-20: Global - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-21: US - Vumerity Annual Sales (US$ Million), 2020-2025
Figure 12-22: US - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-23: US - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-24: ROW - Vumerity Annual Sales (US$ Million), 2020-2025
Figure 12-25: ROW - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-26: ROW - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-27: Rayos - Available Dosage Strengths (mg)
Figure 12-28: Rayos - Price Per Unit & Supply (US$), August'2025
Figure 12-29: US - Rayos Annual Sales (US$ Million), 2020-2023
Figure 12-30: Global - Rayos Quarterly Sales (US$ Million), H1'2023
Figure 12-31: Bafiertam - Price Per Unit & Supply (US$), August'2025
Figure 13-1: Glumetza - Available Dosage Strengths (mg)
Figure 13-2: Glumetza - Price Per Unit & Supply (US$), August'2025
Figure 13-3: Generic Metformin - Price Per Unit & Supply Of 500mg (US$), August'2025
Figure 13-4: Generic Metformin - Price Per Unit & Supply Of 1000mg (US$), August'2025
Figure 13-5: Glucotrol XL - Available Dosage Strengths (mg)
Figure 13-6: Glucotrol XL - Price Per Unit & Supply Of Strength 5 mg (US$), August'2025
Figure 13-7: Glucotrol XL - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
Figure 13-8: Generic Glipizide - Price Per Unit & Supply Of Strength 5 mg (US$), August'2025
Figure 13-9: Generic Glipizide - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
Figure 13-10: Glucophage XR - Available Dosage Strengths (mg)
Figure 13-11: Glucophage XR - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
Figure 13-12: Glucophage XR - Price Per Unit & Supply Of Strength 750 mg (US$), August'2025
Figure 13-13: Trijardy XR - Price Per Unit & Supply Of Strengths 10 mg-5 mg-1000 mg & 25 mg-5 mg-1000 mg (US$), August'2025
Figure 13-14: Trijardy XR - Price Per Unit & Supply Of Strengths 10 mg-5 mg-1000 mg & 25 mg-5 mg-1000 mg (US$), August'2025
Figure 13-15: Synjardy XR - Price Per Unit & Supply Of 10 mg-1000 mg & 25 mg-1000 mg (US$), August'2025
Figure 13-16: Synjardy XR - Price Per Unit & Supply Of 5 mg-1000 mg & 12.5 mg-1000 mg (US$), August'2025
Figure 14-1: Procardia XL - Available Dosage Strengths (mg)
Figure 14-2: Procardia XL - Price Per Unit & Supply Of 100 Tablets (US$), August'2025
Figure 14-3: Procardia XL - Price Per Unit & Supply Of 300 Tablets (US$), August'2025
Figure 14-4: Toprol XL - Available Dosage Strengths
Figure 14-5: Toprol XL - Price Per Unit & Supply Of Strengths 25 mg, 50 mg & 200 mg (US$), August'2025
Figure 14-6: Toprol XL - Price Per Unit & Supply Of Strengths 100 mg (US$), August'2025
Figure 14-7: Global - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-8: Global - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 14-9: US - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-10: EU - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 14-11: EU - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-12: EU - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 14-13: ROW - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-14: ROW - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 14-15: Verelan PM - Available Dosage Strengths (mg)
Figure 14-16: Verelan PM - Price Per Unit & Supply (US$), August'2025
Figure 14-17: Generic Verapamil - Price Per Unit & Supply (US$), August'2025
Figure 14-18: Cardizem LA - Available Dosage Strengths (mg)
Figure 14-19: Cardizem LA - Price Per Unit & Supply Of 30 Tablets (US$), August'2025
Figure 14-20: Cardizem LA - Price Per Unit & Supply Of 90 Tablets (US$), August'2025
Figure 14-21: Calan SR - Available Dosage Strengths (mg)
Figure 14-22: Calan SR - Price Per Unit & Supply Of 120 mg & 180 mg (US$), August'2025
Figure 14-23: Calan SR - Price Per Unit & Supply Of 240 mg (US$), August'2025
Figure 14-24: Altoprev - Available Dosage Strengths (mg)
Figure 14-25: Altoprev - Price Per Unit & Supply (US$), August'2025
Figure 14-26: Cardura XL - Available Dosage Strengths (mg)
Figure 14-27: Cardura XL - Price Per Unit & Supply (US$), August'2025
Figure 15-1: Apretude - Price Per Unit & Supply (US$), August'2025
Figure 15-2: Cabenuva - Price Per Unit & Supply (US$), August'2025
Figure 15-3: Rukobia - Price Per Unit & Supply (US$), August'2025
Figure 16-1: Qelbree - Price Per Unit & Supply Of Strengths 100 mg & 150 mg (US$), August'2025
Figure 16-2: Qelbree - Price Per Unit & Supply Of Strength 200 mg (US$), August'2025
Figure 16-3: Global - Qelbree Annual Sales (US$ Million), 2021-2023
Figure 16-4: Global - Qelbree Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 16-5: Global - Qelbree Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 16-6: Jornay PM - Available Dosage Strengths (mg)
Figure 16-7: Jornay PM - Price Per Unit & Supply (US$), August'2025
Figure 16-8: Global - Jornay PM Annual Sales (US$ Million), 2024-2025
Figure 16-9: Global - Jornay PM Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 16-10: Global - Jornay PM Quarterly Sales (US$ Million), Q3-Q4'2024
Figure 16-11: Cotempla XR-ODT - Available Dosage Strengths (mg)
Figure 16-12: Cotempla XR-ODT - Price Per Unit & Supply (US$), August'2025
Figure 16-13: Adzenys XR-ODT - Available Dosage Strengths (mg)
Figure 16-14: Adzenys XR-ODT - Price Per Unit & Supply (US$), August'2025
Figure 16-15: Global - Adzenys XR-ODT & Cotempla XR-ODT Annual Sales (US$ Million), 2021-2025
Figure 16-16: Global - Adzenys XR-ODT & Cotempla XR-ODT Quarterly Sales (US$ Million), Q1'2025
Figure 16-17: Global - Adzenys XR-ODT & Cotempla XR-ODT Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 16-18: Intuniv - Available Dosage Strengths (mg)
Figure 16-19: Intuniv - Price Per Unit & Supply (US$), August'2025
Figure 16-20: Global - Intuniv Annual Sales (US$ Million), 2020-2025
Figure 16-21: Global - Intuniv Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 16-22: Focalin XR - Available Dosage Strengths (mg)
Figure 16-23: Focalin XR - Price Per Unit & Supply (US$), August'2025
Figure 17-1: Rinvoq - Available Dosage Strengths (mg)
Figure 17-2: Rinvoq - Price Per Unit & Supply (US$), August'2025
Figure 17-3: Global - Rinvoq Annual Sales (US$ Million), 2020-2025
Figure 17-4: Global - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-5: Global - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-6: US - Rinvoq Annual Sales (US$ Million), 2020-2025
Figure 17-7: US - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-8: US - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-9: ROW - Rinvoq Annual Sales (US$ Million), 2020-2025
Figure 17-10: ROW - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-11: ROW - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-12: Ortikos - Available Dosage Strengths (mg)
Figure 17-13: Ortikos - Price Per Unit & Supply (US$), August'2025
Figure 17-14: Xeljanz XR - Available Dosage Strengths (mg)
Figure 17-15: Xeljanz XR - Price Per Unit & Supply (US$), August'2025
Figure 17-16: Global - Xeljanz XR Annual Sales (US$ Million), 2020-2025
Figure 17-17: Global - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-18: Global - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-19: US - Xeljanz XR Annual Sales (US$ Million), 2020-2025
Figure 17-20: US - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-21: US - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-22: ROW - Xeljanz XR Annual Sales (US$ Million), 2020-2025
Figure 17-23: ROW - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-24: ROW - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-25: Mestinon Timespan - Price Per Unit & Supply (US$), August'2025
Figure 17-26: Generic Pyridostigmine - Price Per Unit & Supply (US$), August'2025
Figure 17-27: Symax Duotab - Price Per Unit & Supply (US$), August'2025
Figure 18-1: Aemcolo - Price Per Unit & Supply (US$), August'2025
Figure 18-2: Talicia - Price Per Unit & Supply (US$), August'2025
Figure 19-1: Sublocade - Price Per Unit & Supply (US$), August'2025
Figure 19-2: Global - Sublocade Annual Sales (US$ Million), 2020-2025
Figure 19-3: Global - Sublocade Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 19-4: Global - Sublocade Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 19-5: Sublocade - Price Per Unit & Supply Of Strength 50 mg/mL (US$), August'2025
Figure 19-6: Sublocade - Price Per Unit & Supply Of Strength 355.6 mg/mL (US$), August'2025
Figure 20-1: Astagraf XL - Available Dosage Strengths (mg)
Figure 20-2: Astagraf XL - Price per Unit & Supply (US$), August'2025
Figure 20-3: Envarsus XR - Available Dosage Strengths (mg)
Figure 20-4: Envarsus XR - Price per Unit & Supply Of 30 Tablets (US$), August'2025
Figure 20-5: Envarsus XR - Price per Unit & Supply Of 100 Tablets (US$), August'2025
Figure 21-1: Trokendi XR - Available Dosage Strengths (mg)
Figure 21-2: Trokendi XR - Price per Unit & Supply (US$), August'2025
Figure 21-3: Global - Trokendi XR Annual Sales (US$ Million), 2020-2025
Figure 21-4: Global - Trokendi XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 21-5: Global - Trokendi XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 21-6: Global - Oxtellar XR Annual Sales (US$ Million), 2020-2025
Figure 21-7: Global - Oxtellar XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 21-8: Global - Oxtellar XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 21-9: Keppra XR - Available Dosage Strengths (mg)
Figure 21-10: Keppra XR - Price per Unit & Supply (US$), August'2025
Figure 21-11: Generic levetiracetam - Price per Unit & Supply Of 500 mg (US$), August'2025
Figure 21-12: Keppra XR - Price per Unit & Supply (US$), August'2025
Figure 21-13: Global - Oxtellar XR Annual Sales (US$ Million), 2020-2025
Figure 21-14: Roweepra XR - Available Dosage Strengths (mg)
Figure 21-15: Roweepra XR - Price per Unit & Supply (US$), August'2025
Figure 21-16: Depakote - Available Dosage Strengths (mg)
Figure 21-17: Depakote - Price per Unit & Supply (US$), August'2025
Figure 21-18: Depakote ER - Available Dosage Strengths (mg)
Figure 21-19: Depakote ER - Price per Unit & Supply (US$), August'2025
Figure 21-20: Depakote Sprinkles - Price per Unit & Supply (US$), August'2025
Figure 22-1: Effexor XR - Available Dosage Strengths (mg)
Figure 22-2: Effexor XR - Price per Unit & Supply Of 30 Capsules (US$), August'2025
Figure 22-3: Effexor XR - Price per Unit & Supply Of 90 Capsules (US$), August'2025
Figure 22-4: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
Figure 22-5: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
Figure 22-6: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
Figure 22-7: Global - Effexor XR Annual Sales (US$ Million), 201-2025
Figure 22-8: Global - Effexor XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 22-9: Global - Effexor XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 22-10: Xanax XR - Available Dosage Strengths (mg)
Figure 22-11: Xanax XR - Price per Unit & Supply (US$), August'2025
Figure 22-12: Generic Alprazolam - Price per Unit & Supply (US$), August'2025
Figure 22-13: Ambien CR - Available Dosage Strengths (mg)
Figure 22-14: Ambien CR - Price per Unit & Supply (US$), August'2025
Figure 22-15: Generic Zolpidem - Price per Unit & Supply Of 6.25 mg (US$), August'2025
Figure 22-16: Generic Zolpidem - Price per Unit & Supply Of 12.5 mg (US$), August'2025
Figure 23-1: Klor-Con 8 - Price per Unit & Supply (US$), August'2025
Figure 23-2: Generic Potassium Chloride - Price per Unit & Supply Of 8 mEq (US$), August'2025
Figure 23-3: Klor-Con 10 - Price per Unit & Supply (US$), August'2025
Figure 23-4: Klor-Con M10 - Price per Unit & Supply (US$), August'2025
Figure 23-5: Klor-Con M15 - Price per Unit & Supply (US$), August'2025
Figure 23-6: Generic Potassium Chloride - Price per Unit & Supply Of 15 mEq (US$), August'2025
Figure 23-7: Klor-Con M20 - Price per Unit & Supply (US$), August'2025
Figure 24-1: Controlled Drug Delivery System Market - Key Drivers
Figure 24-2: Controlled Drug Delivery System Market - Major Challenges

List of Tables

Table 1-1: Conventional vs. Novel Drug Delivery
Table 1-2: Sustained vs. Controlled Release
Table 5-1: Controlled Release Drugs - Recent US FDA Approvals

02-2729-4219

+886-2-2729-4219

License/价格

药物输送的全球市场:药物用量，药价，销售额，临床试验趋势(2030年)

Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales & Clinical Trials Insight 2030

目录

第1章 控制型药物输送的简介

第2章 控制型药物输送的基于材料方法

第3章 全球缓释性药物输送市场趋势

第4章 控製药物输送的研究和临床趋势，各适应症

第5章 全球缓释性医药品市场趋势，各地区

第6章 各企业，各适应症，各期的世界缓释性医药品的临床实验平台

第7章 上市的缓释性医药品的各企业，各国，各适应症的临床性洞察

第8章 阿兹海默症的缓释性药物- 价格和用量的考察

第9章 帕金森氏症的缓释性药物- 价格和用量的考察

第10章 思觉失调症的缓释性药物- 价格和用量的考察

第11章 对慢性疼痛及手术后疼痛的缓释性药物- 价格和用量的考察

第12章 对多发性硬化症的缓释性药物- 价格和用量的考察

第13章 对第二型糖尿病的缓释性药物- 价格和用量的考察

第14章 对心血管疾病的缓释性药物- 价格和用量的考察

第15章 对HIV的缓释性药物- 价格和用量的考察

第16章 对注意缺陷·多动性障碍(ADHD)的缓释性药物- 价格和用量的考察

第17章 对发炎性疾病及自体免疫疾病的缓释性药物- 价格和用量的考察

第18章 对细菌感染疾病的缓释性药物- 价格和用量的考察

第19章 对类鸦片物质使用障碍的缓释性药物- 价格和用量的考察

第20章 器官移植排斥反应抑制的缓释性药物- 价格和用量的考察

第21章 与偏头痛对发作的缓释性药物- 价格和用量的考察

第22章 对精神疾病及睡眠障碍的缓释性药物- 价格和用量的考察

第23章 对代谢·电解质异常的缓释性药物- 价格和用量的考察

第24章 世界的药物递输系统市场动态

第25章 竞争情形

Table of Contents

1. Introduction To Controlled Drug Delivery

2. Material Based Approaches For Controlled Drug Delivery

3. Global Controlled Release Drug Delivery Market Trends

4. Controlled Drug Delivery Research & Clinical Trends By Indication

5. Global Controlled Release Drug Market Trends By Region

6. Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase

7. Marketed Controlled Release Drugs Clinical Insight By Company, Country & Indication

8. Controlled Release Drugs for Alzheimer's Disease - Pricing & Dosage Insight

9. Controlled Release Drugs for Parkinson's Disease - Pricing & Dosage Insight

10. Controlled Release Drugs for Schizophrenia - Pricing & Dosage Insight

11. Controlled Release Drugs for Chronic & Post-Operative Pain - Pricing & Dosage Insight

12. Controlled Release Drugs for Multiple Sclerosis - Pricing & Dosage Insight

13. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing & Dosage Insight

14. Controlled Release Drugs for Cardiovascular Diseases - Pricing & Dosage Insight

15. Controlled Release Drugs for HIV - Pricing & Dosage Insight

16. Controlled Release Drugs for Attention Deficit Hyperactivity Disorder - Pricing & Dosage Insight

17. Controlled Release Drugs for Inflammatory & Autoimmune Diseases - Pricing & Dosage Insight

18. Controlled Release Drugs for Bacterial Infections - Pricing & Dosage Insight

19. Controlled Release Drugs for Opioid Use Disorder - Pricing & Dosage Insight

20. Controlled Release Drugs for Preventing Organ Transplant Rejection - Pricing & Dosage Insight

21. Controlled Release Drugs for Migraine & Seizure - Pricing & Dosage Insight

22. Controlled Release Drugs for Mental Health and Sleep Disorders - Pricing & Dosage Insight

23. Controlled Release Drugs for Metabolic and Electrolyte Disorders - Pricing & Dosage Insight

24. Global Controlled Drug Delivery System Market Dynamics

25. Competitive Landscape

List of Figures

List of Tables

第1章控制型药物输送的简介

第2章控制型药物输送的基于材料方法

第3章全球缓释性药物输送市场趋势

第4章控製药物输送的研究和临床趋势，各适应症

第5章全球缓释性医药品市场趋势，各地区

第6章各企业，各适应症，各期的世界缓释性医药品的临床实验平台

第7章上市的缓释性医药品的各企业，各国，各适应症的临床性洞察

第8章阿兹海默症的缓释性药物- 价格和用量的考察

第9章帕金森氏症的缓释性药物- 价格和用量的考察

第10章思觉失调症的缓释性药物- 价格和用量的考察

第11章对慢性疼痛及手术后疼痛的缓释性药物- 价格和用量的考察

第12章对多发性硬化症的缓释性药物- 价格和用量的考察

第13章对第二型糖尿病的缓释性药物- 价格和用量的考察

第14章对心血管疾病的缓释性药物- 价格和用量的考察

第15章对HIV的缓释性药物- 价格和用量的考察

第16章对注意缺陷·多动性障碍(ADHD)的缓释性药物- 价格和用量的考察

第17章对发炎性疾病及自体免疫疾病的缓释性药物- 价格和用量的考察

第18章对细菌感染疾病的缓释性药物- 价格和用量的考察

第19章对类鸦片物质使用障碍的缓释性药物- 价格和用量的考察

第20章器官移植排斥反应抑制的缓释性药物- 价格和用量的考察

第21章与偏头痛对发作的缓释性药物- 价格和用量的考察

第22章对精神疾病及睡眠障碍的缓释性药物- 价格和用量的考察

第23章对代谢·电解质异常的缓释性药物- 价格和用量的考察

第24章世界的药物递输系统市场动态

第25章竞争情形